sFRP2Secreted Frizzled Related Protein 2 (gene)
References in periodicals archive ?
For the present study, we chose well-known genes, regulation regions of which were often hypermethylated at colorectal cancer: SEPT9, FBN1, VIM, SDC2, THBD, SFRP2, ESR1, TMEFF2, NGFR, ALX4, HLTF, and NEUROG1 [20,21].
3) -- HLTF Helicase like transcription factor LAMA1 Laminin subunit alpha 1 NEUROG1 NEUROG1 Neurogenin 1 NGFR NGFR Nerve growth factor receptor RARB RARB Retinoic acid receptor beta RXRG RXRG Retinoid X receptor gamma RYR2 RYR2 Ryanodine receptor 2 SDC2 SDC2 Syndecan 2 SEPT9 SEPT9 Septin 9 SFRP2 SFRP2 Secreted frizzled-related SOCS3 SOCS3 Suppressor of cytokine signaling 3 SOX17 SOX17 SRY-box 17 THBD THBD Thrombomodulin Transmembrane protein with TMEFF2 TMEFF2 EGF-like and two follista- tin-like domains 2 UCHL1 UCHL1 Ubiquitin C-torminal hydro-lase L1 VIM VIM Vimentin Gene (a) Chromosomal (region) location (a) ADHFE1 8q12.
Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
For their research, the team studied mice that did not produce sFRP2, to understand how the protein works.
The researchers suggest that identifying agents that specifically target sFRP2 and inhibits its activity can help control heart attack-induced scarring and impaired heart function,
The methylated form of the gene SFRP2 is by itself one of the most sensitive markers for identifying colorectal cancer through the analysis of DNA in stool samples, reported Dr.
In an integrated genetic/epigenetic approach, Serizawa et al (94) prospectively performed mutational screening of a set of 6 genes (FGFR3, PIK3CA, TP53, HRAS, NRAS, and KRAS) and quantitatively assessed promoter methylation status of 11 additional genes (APC, ARF, DBC1, INK4A, RARB, RASSF1A, SFRP1, SFRP2, SFRP4, SFRP5, and WIF1) in NMI-BC tumor biopsy specimens and corresponding urine samples from 118 patients and 33 controls.
On the other hand, three apparently healthy individuals were found to have methylated SFRP2 in their stool (77% specificity).
In contrast, WNT8A and some WNT antagonists (DKK1, SFRP2, and SFRP4) were down-regulated.